HRP20100276T1 - Gaboksadol za liječenje depresije i drugih afektivnih poremećaja - Google Patents
Gaboksadol za liječenje depresije i drugih afektivnih poremećaja Download PDFInfo
- Publication number
- HRP20100276T1 HRP20100276T1 HR20100276T HRP20100276T HRP20100276T1 HR P20100276 T1 HRP20100276 T1 HR P20100276T1 HR 20100276 T HR20100276 T HR 20100276T HR P20100276 T HRP20100276 T HR P20100276T HR P20100276 T1 HRP20100276 T1 HR P20100276T1
- Authority
- HR
- Croatia
- Prior art keywords
- gaboxadol
- treating depression
- pharmaceutical composition
- oral dose
- affective disorders
- Prior art date
Links
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 title claims abstract 10
- 229950004346 gaboxadol Drugs 0.000 title claims abstract 10
- 208000019022 Mood disease Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 2
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 150000004682 monohydrates Chemical class 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 abstract 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48301903P | 2003-06-25 | 2003-06-25 | |
| DKPA200300956 | 2003-06-25 | ||
| US53512304P | 2004-01-07 | 2004-01-07 | |
| DKPA200400016 | 2004-01-07 | ||
| PCT/DK2004/000459 WO2004112786A2 (fr) | 2003-06-25 | 2004-06-25 | Traitement de la depression et d'autres troubles affectifs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100276T1 true HRP20100276T1 (hr) | 2010-06-30 |
Family
ID=33545397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100276T HRP20100276T1 (hr) | 2003-06-25 | 2010-05-18 | Gaboksadol za liječenje depresije i drugih afektivnih poremećaja |
Country Status (17)
| Country | Link |
|---|---|
| EP (2) | EP2145620A3 (fr) |
| JP (1) | JP2007508236A (fr) |
| AT (1) | ATE459353T1 (fr) |
| AU (1) | AU2004248890A1 (fr) |
| BR (1) | BRPI0410857A (fr) |
| CY (1) | CY1110046T1 (fr) |
| DE (1) | DE602004025808D1 (fr) |
| DK (1) | DK1641456T3 (fr) |
| ES (1) | ES2341004T3 (fr) |
| HR (1) | HRP20100276T1 (fr) |
| IL (2) | IL172631A0 (fr) |
| MX (1) | MXPA05013016A (fr) |
| NZ (1) | NZ543586A (fr) |
| PL (1) | PL1641456T3 (fr) |
| PT (1) | PT1641456E (fr) |
| SI (1) | SI1641456T1 (fr) |
| WO (1) | WO2004112786A2 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005023256A1 (fr) * | 2003-09-10 | 2005-03-17 | Merck Sharp & Dohme Limited | Utilisation d'agonistes des recepteurs gabaa pour traiter les troubles auditifs, vestibulaires et de l'attention, le tremblement intentionnel et le syndrome des jambes sans repos |
| EP1691811B1 (fr) | 2003-12-11 | 2014-07-23 | Sunovion Pharmaceuticals Inc. | Combinaison d'un sedatif et d'un modulateur des neurotransmetteurs, et methodes permettant d'ameliorer la qualite du sommeil et de traiter la depression |
| GB0402118D0 (en) * | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
| DK1742624T3 (da) | 2004-02-18 | 2010-03-08 | Sepracor Inc | Dopamin-agonist-kombinationsterapi med sedativer til forbedring af søvnkvalitet |
| GB0417558D0 (en) * | 2004-08-06 | 2004-09-08 | Merck Sharp & Dohme | Novel combination therapy |
| EP1848420A4 (fr) * | 2005-01-28 | 2008-01-23 | Merck & Co Inc | Formes polymorphes d'un agoniste gabaa |
| US20080262029A1 (en) * | 2005-04-29 | 2008-10-23 | H. Lundbeck A/S | Acid and Base Salt Forms of Gaboxadol |
| TW200920358A (en) * | 2007-08-13 | 2009-05-16 | Lundbeck & Co As H | Method of treating stress-mediated depression |
| US20090143335A1 (en) * | 2007-10-29 | 2009-06-04 | H. Lundbeck A/S | Modified absorption formulation of gaboxadol |
| EP2334299A1 (fr) * | 2008-09-01 | 2011-06-22 | H. Lundbeck A/S | Composition pharmaceutique comprenant du gaboxadol et un inhibiteur de pat1 ou d'oat |
| LT3274331T (lt) | 2015-03-24 | 2020-04-10 | H. Lundbeck A/S | 4,5,6,7-tetrahidroizozaksolo[5,4-c]piridin-3-olio gamybos būdas |
| CN110225754A (zh) * | 2016-11-22 | 2019-09-10 | 奥维德医疗公司 | 用氟吡汀治疗发育障碍和/或癫痫发作紊乱的方法 |
| US20180338959A1 (en) * | 2017-05-24 | 2018-11-29 | Ovid Therapeutics Inc. | Treatment of depressive disorders |
| WO2019195813A1 (fr) * | 2018-04-06 | 2019-10-10 | Ovid Therapeutics Inc. | Utilisation de gaboxadol dans le traitement de troubles liés à l'usage de substances |
| US10765666B2 (en) | 2018-09-20 | 2020-09-08 | Ovid Therapeutics Inc | Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering |
| US11123332B2 (en) | 2018-11-21 | 2021-09-21 | Certego Therapeutics Inc. | Gaboxadol for reducing risk of suicide and rapid relief of depression |
| WO2020106976A1 (fr) * | 2018-11-21 | 2020-05-28 | Certego Therapeutics | Combinaison de gaboxol et de lithium pour le traitement de troubles psychiatriques |
| CN113423399A (zh) | 2018-12-17 | 2021-09-21 | 奥维德医疗公司 | 加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途 |
| MX2022007715A (es) | 2019-12-18 | 2022-07-19 | Ovid Therapeutics Inc | Gaboxadol para el tratamiento terapeutico del sindrome de delecion 1p36. |
| AU2021275863A1 (en) | 2020-05-20 | 2023-02-02 | Certego Therapeutics Inc. | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK270378A (da) | 1977-06-20 | 1978-12-21 | Krogsgaard Larsen P | Isoxazolderivater |
| DE19525598C2 (de) | 1995-07-13 | 1997-09-25 | Max Planck Gesellschaft | Schlafmittel |
| AR031473A1 (es) * | 2000-11-20 | 2003-09-24 | Lundbeck & Co As H | Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide |
| US20020165217A1 (en) * | 2001-05-01 | 2002-11-07 | Pfizer Inc. | Combination treatment for anxiety and depression |
| AU2002338855B2 (en) | 2001-05-21 | 2007-08-16 | H. Lundbeck A/S | Granular preparations of gaboxadol |
-
2004
- 2004-06-25 DE DE602004025808T patent/DE602004025808D1/de not_active Expired - Lifetime
- 2004-06-25 DK DK04738956.4T patent/DK1641456T3/da active
- 2004-06-25 WO PCT/DK2004/000459 patent/WO2004112786A2/fr active Application Filing
- 2004-06-25 PL PL04738956T patent/PL1641456T3/pl unknown
- 2004-06-25 BR BRPI0410857-4A patent/BRPI0410857A/pt not_active IP Right Cessation
- 2004-06-25 AT AT04738956T patent/ATE459353T1/de not_active IP Right Cessation
- 2004-06-25 NZ NZ543586A patent/NZ543586A/en unknown
- 2004-06-25 JP JP2006515735A patent/JP2007508236A/ja active Pending
- 2004-06-25 ES ES04738956T patent/ES2341004T3/es not_active Expired - Lifetime
- 2004-06-25 EP EP09173892A patent/EP2145620A3/fr not_active Withdrawn
- 2004-06-25 PT PT04738956T patent/PT1641456E/pt unknown
- 2004-06-25 MX MXPA05013016A patent/MXPA05013016A/es active IP Right Grant
- 2004-06-25 AU AU2004248890A patent/AU2004248890A1/en not_active Abandoned
- 2004-06-25 EP EP04738956A patent/EP1641456B1/fr not_active Expired - Lifetime
- 2004-06-25 SI SI200431414T patent/SI1641456T1/sl unknown
-
2005
- 2005-12-15 IL IL172631A patent/IL172631A0/en unknown
-
2009
- 2009-11-12 IL IL202106A patent/IL202106A0/en unknown
-
2010
- 2010-05-14 CY CY20101100433T patent/CY1110046T1/el unknown
- 2010-05-18 HR HR20100276T patent/HRP20100276T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2145620A2 (fr) | 2010-01-20 |
| DE602004025808D1 (de) | 2010-04-15 |
| AU2004248890A1 (en) | 2004-12-29 |
| CY1110046T1 (el) | 2015-01-14 |
| EP1641456B1 (fr) | 2010-03-03 |
| EP1641456A2 (fr) | 2006-04-05 |
| EP2145620A3 (fr) | 2010-03-17 |
| NZ543586A (en) | 2009-07-31 |
| PT1641456E (pt) | 2010-06-01 |
| ES2341004T3 (es) | 2010-06-14 |
| WO2004112786A3 (fr) | 2005-04-14 |
| ATE459353T1 (de) | 2010-03-15 |
| DK1641456T3 (da) | 2010-06-21 |
| SI1641456T1 (sl) | 2010-06-30 |
| BRPI0410857A (pt) | 2006-07-04 |
| MXPA05013016A (es) | 2006-03-02 |
| PL1641456T3 (pl) | 2010-08-31 |
| IL172631A0 (en) | 2006-04-10 |
| WO2004112786A2 (fr) | 2004-12-29 |
| JP2007508236A (ja) | 2007-04-05 |
| IL202106A0 (en) | 2010-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100276T1 (hr) | Gaboksadol za liječenje depresije i drugih afektivnih poremećaja | |
| MX2009011755A (es) | Terapia de combinacion con un compuesto que actua como un inhibidor del receptor adp de plaquetas. | |
| SG150531A1 (en) | Use of meloxicam for the treatment of respiratory diseases in pigs | |
| MA32692B1 (fr) | Procede de liberation d'une composition pharmaceutique a un patient qui en a besoin | |
| BRPI0512213A (pt) | método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto | |
| ATE414519T1 (de) | Kombination aus einem nmda-antagonist und acetylcholinesterase-hemmern zur behandlung der alzheimer-krankheit | |
| WO2007038112A3 (fr) | Composition pharmaceutique conçue pour ameliorer la fonction cognitive | |
| UA86621C2 (ru) | Антагонисты рецептора глюкагона, их получение и терапевтическое применение | |
| HRP20221269T1 (hr) | Pripravci za liječenje mijelofibroze | |
| BR0215148A (pt) | Composições farmacêuticas de agonista parcial 5ht4 | |
| BR0314488A (pt) | Composto, composição farmacêutica e métodos de tratamento | |
| RU2012142811A (ru) | Фармацевтические композиции и пероральные дозированные формы пролекарства леводопы и способы применения | |
| MXPA06000705A (es) | Combinacion de antagonista del receptor 2 de glutamato metabotropico (mglur2) e inhibidor de acetilcolinesterasa (ache) para tratar trastornos neurologicos agudos y/o cronicos. | |
| MX2007012300A (es) | Uso de nefopam y analogos del mismo para el tratamiento de un sindrome caracterizado por dolor cronico y fatiga. | |
| ATE505203T1 (de) | Pharmazeutische kombination aus aliskiren und valsartan | |
| MXPA05011432A (es) | Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina. | |
| TW200603816A (en) | Risedronate compositions and their methods of use | |
| BR0214497A (pt) | Composição farmacêutica que compreende um agonista do receptor 5ht1 | |
| IL168704A (en) | Calcilytic compounds, pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising them and their use in the preparation of medicaments for treating disease or disorder characterized by abnormal bone or mineral homeostasis | |
| MXPA05011476A (es) | Imidazolin-2-il-aminofenil-amidas como antagonistas de prostaglandina i2. | |
| WO2007062862A3 (fr) | Utilisation d'inhibiteurs de la calmoduline pour traiter des troubles neurodegeneratifs | |
| Hong et al. | Role of central α2-adrenoceptors on the development of muricidal behavior in olfactory bulbectomized rats: Effect of α2-adrenoceptor antagonists | |
| WO2005121074A3 (fr) | Procedes pour la preparation de chlorhydrate de sertraline | |
| HRP20090102T3 (en) | Improved pharmaceutical composition containing ace inhibitor and method for the preparation thereof | |
| BRPI0415546A (pt) | composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, e de distúrbios |